查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1679172

乳房復发评分检测市场：全球产业分析、规模、份额、成长、趋势及预测（2025-2032）

Breast Recurrence Score Test Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 233 Pages | 商品交期: 2-5个工作天内

价格
简介目录

Persistence Market Research 最近发布了一份关于全球乳癌復发评分测试市场的综合报告。该报告对市场驱动因素、趋势、机会、驱动因素和挑战等关键市场动态进行了全面评估，并对市场结构提供了详细的见解。本研究报告提供独家资料和统计数据，概述了 2025 年至 2032 年全球乳房復发评分测试市场的预期成长轨迹。

关键见解

  • 乳癌復发评分测试市场规模（2025年）：2.811亿美元
  • 市场预测（2032 年）：5.295 亿美元
  • 全球市场成长率（2025-2032年复合年增长率）：9.5%

乳癌復发评分测试市场-报告内容：

乳房復发评分测试是一种基因组检测，用于评估早期乳癌患者癌症復发的可能性。此测试可帮助肿瘤科医师确定是否需要化疗，从而实现更个人化的治疗方法。乳房復发评分测试市场的目标是医院、诊断实验室、研究机构和专门的肿瘤中心。市场成长的动力来自于精准医疗意识的不断增强、乳癌发病率的上升以及基因组检测在临床决策中的日益普及。

市场驱动因素：

全球乳房復发评分测试市场受到几个关键因素的推动，例如全球乳癌发生率的增加和个人化医疗需求的增加。基因组检测技术的进步，加上肿瘤学对分子诊断的日益接受，将进一步推动市场扩张。支持基因检测的报销政策以及政府推动癌症筛检计画的措施不断增加也促进了市场的扩张。此外，向非侵入性、经济高效的诊断解决方案的转变正在推动乳房復发评分测试的采用。

市场限制：

儘管成长前景看好，但乳房復发评分测试市场仍面临着与法规遵循、测试成本高以及新兴地区认知度低相关的挑战。基因组检测的严格监管核准和各国不同的报销政策是市场渗透的障碍。此外，乳癌復发评分测试的高成本可能会限制其在低收入国家的普及，从而抑制其应用。应对这些挑战需要监管机构、医疗保健提供者和市场相关人员共同努力，提高测试的可负担性和可近性。

市场机会：

由于技术进步、癌症研究投资的增加以及基因组检测在肿瘤学中的应用不断扩大，乳房復发评分测试市场提供了巨大的成长机会。人工智慧 (AI) 和机器学习在基因组资料解释中的整合将提高测试准确性并支援临床决策。此外，製药公司和诊断公司之间为开发先进的分子检测解决方案而建立的策略联盟将为市场扩张开闢新的途径。人们对早期癌症检测的日益关注，加上政府推动精准医疗的倡议，为市场参与者提供了进一步创新和加强其影响力的机会。

本报告探讨的关键问题

  • 推动全球乳房復发评分测试市场成长的关键因素有哪些？
  • 哪些医疗机构正在率先采用乳房復发评分测试？
  • 技术进步如何影响乳房復发评分测试市场的竞争格局？
  • 哪些主要企业为市场做出了贡献？他们采取了哪些策略来维持市场相关性？
  • 全球乳房復发评分测验市场的新兴趋势和未来前景是什么？

目录

第一章执行摘要

第二章 市场概述

  • 市场范围和定义
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
    • 主要趋势
  • 宏观经济因素
    • 全球产业展望
    • 全球GDP成长前景
  • COVID-19影响分析
  • 预测因子－相关性和影响力

第三章 增值洞察

  • 产品采用分析
  • 监管状况
  • 价值链分析
  • PESTLE分析
  • 波特五力分析

第四章全球乳房復发评分测试市场展望

  • 主要亮点
    • 市场规模及与前一年同期比较率
    • 绝对的商机
  • 市场规模分析与预测
    • 2019-2024 年历史市场规模分析
    • 目前市场规模分析与预测，2025-2032
  • 全球乳房復发评分测试市场展望：产品
    • 简介/主要发现
    • 2019 年至 2024 年按产品分類的历史市场规模分析
    • 2025 年至 2032 年按产品分類的当前市场规模分析与预测
      • 检测套组
      • 试剂和耗材
    • 市场吸引力分析：产品
  • 全球乳房復发评分测试市场展望：适应症
    • 简介/主要发现
    • 2019 年至 2024 年各适应症的历史市场规模
    • 目前市场规模分析与预测（按适应症），2025 年至 2032 年
      • 乳癌1期
      • 乳癌2期
      • 雌激素受体阳性癌症
      • 淋巴结阴性癌症
    • 市场吸引力分析：迹象
  • 全球乳房復发评分测试市场展望：最终用户
    • 简介/主要发现
    • 2019 年至 2024 年最终用户市场规模历史分析
    • 2025 年至 2032 年按最终用户分類的当前市场规模分析和预测
      • 医院
      • 专门癌症中心
      • 诊断中心
      • 癌症研究所
    • 市场吸引力分析：最终用户

5. 全球乳房復发评分测试市场（按地区）展望

  • 主要亮点
  • 2019 年至 2024 年各地区历史市场规模分析
  • 2025 年至 2032 年各地区目前市场规模分析与预测
    • 北美洲
    • 欧洲
    • 东亚
    • 南亚和大洋洲
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：地区

6. 北美乳房復发评分测试市场展望

7. 欧洲乳房復发评分测试市场展望

8. 东亚乳房復发评分测试市场展望

9.南亚和大洋洲乳房復发评分测试市场展望

10.拉丁美洲乳房復发评分测试市场展望

11.中东和非洲乳房復发评分测试市场展望

第十二章竞争格局

  • 2024年市场占有率分析
  • 市场结构
    • 市场竞争加剧图
    • 竞争仪錶板
  • 公司简介（详情－概述、财务状况、策略、最新发展）
    • ThermoFisher Scientific
    • Exact Sciences（Genome Health Inc.）
    • NanoString Technologies, Inc.
    • Foundation Medicine, Inc
    • Illumina, Inc
    • Hologic Inc（Biotheranostic）
    • Biocartis
    • Roche Diagnostics
    • Epic Sciences
    • Qiagen
    • Abbott
    • Myriad Genetics, Inc
    • Guardant Health
    • Agendia
    • Genomic Health
    • iCAD
    • CancerIQ
    • Siemens Healthineers
    • General Electric Company
    • Koninklijke Philips NV

第十三章 附录

  • 调查方法
  • 调查前提
  • 首字母缩写和简称
简介目录
Product Code: PMRREP32146

Persistence Market Research has recently released a comprehensive report on the worldwide market for Breast Recurrence Score Tests. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global Breast Recurrence Score Test Market from 2025 to 2032.

Key Insights:

  • Breast Recurrence Score Test Market Size (2025E): US$ 281.1 Mn
  • Projected Market Value (2032F): US$ 529.5 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 9.5%

Breast Recurrence Score Test Market - Report Scope:

The Breast Recurrence Score Test is a genomic assay used to assess the likelihood of cancer recurrence in patients diagnosed with early-stage breast cancer. This test aids oncologists in determining the necessity of chemotherapy, allowing for more personalized treatment approaches. The market for breast recurrence score tests caters to hospitals, diagnostic laboratories, research institutions, and specialty oncology centers. Market growth is fueled by increasing awareness of precision medicine, rising breast cancer prevalence, and the growing adoption of genomic testing in clinical decision-making.

Market Growth Drivers:

The global Breast Recurrence Score Test Market is propelled by several key factors, including the increasing incidence of breast cancer worldwide and the growing demand for personalized medicine. Advancements in genomic testing technologies, coupled with the rising acceptance of molecular diagnostics in oncology, further drive market expansion. The availability of reimbursement policies supporting genetic testing and increasing government initiatives promoting cancer screening programs also contribute to market growth. Furthermore, the shift towards non-invasive and cost-effective diagnostic solutions encourages the adoption of breast recurrence score tests.

Market Restraints:

Despite its promising growth, the Breast Recurrence Score Test Market faces challenges related to regulatory compliance, high testing costs, and limited awareness in developing regions. Stringent regulatory approvals for genomic tests and variations in reimbursement policies across different countries pose hurdles for market penetration. Additionally, the high cost associated with breast recurrence score tests may limit their accessibility in low-income countries, restricting widespread adoption. Addressing these challenges requires collaborative efforts between regulatory authorities, healthcare providers, and market players to enhance test affordability and accessibility.

Market Opportunities:

The Breast Recurrence Score Test Market presents significant growth opportunities driven by technological advancements, increased investments in cancer research, and the expanding applications of genomic testing in oncology. The integration of artificial intelligence (AI) and machine learning in genomic data interpretation enhances test accuracy and supports clinical decision-making. Furthermore, strategic partnerships between pharmaceutical companies and diagnostic firms for the development of advanced molecular testing solutions create new avenues for market expansion. The growing focus on early cancer detection, coupled with government initiatives promoting precision medicine, offers further opportunities for market players to innovate and strengthen their presence.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Breast Recurrence Score Test Market globally?
  • Which healthcare settings are leading in the adoption of breast recurrence score tests?
  • How are technological advancements shaping the competitive landscape of the Breast Recurrence Score Test Market?
  • Who are the key players contributing to the market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global Breast Recurrence Score Test Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Breast Recurrence Score Test Market, including Exact Sciences Corporation, Myriad Genetics, Inc., and Agendia Inc., focus on innovation, clinical validation, and strategic collaborations to strengthen their market presence. These companies invest in research and development to enhance the accuracy and predictive capabilities of genomic assays. Partnerships with healthcare providers, research institutions, and biotechnology firms facilitate the integration of breast recurrence score tests into clinical workflows. Additionally, efforts to expand test accessibility through reimbursement policies and awareness campaigns contribute to market growth and patient adoption.

Key Companies Profiled:

  • Exact Sciences Corporation
  • Myriad Genetics, Inc.
  • Agendia Inc.
  • BioTheranostics, Inc.
  • Genomic Health, Inc. (A subsidiary of Exact Sciences)
  • NanoString Technologies, Inc.
  • NeoGenomics Laboratories, Inc.
  • Guardant Health, Inc.
  • OncoDNA S.A.
  • LabCorp (Laboratory Corporation of America)

Breast Recurrence Score Market Segmentation

Product:

  • Test Kits
  • Reagents & Consumables

Indication:

  • Stage 1 Breast Cancer
  • Stage 2 Breast Cancer
  • Estrogen-Receptor-Positive Cancer
  • Lymph-Node-Negative Cancer

End User:

  • Hospitals
  • Specialty Cancer Centers
  • Diagnostic Centers
  • Cancer Research Institutions

Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa
  • Latin America

Table of Contents

1. Executive Summary

  • 1.1. Global Breast Recurrence Score Test Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Value Chain Analysis
  • 3.4. PESTLE Analysis
  • 3.5. Porter's Five Force Analysis

4. Global Breast Recurrence Score Test Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Breast Recurrence Score Test Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. Test Kits
      • 4.3.3.2. Reagents & Consumables
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Breast Recurrence Score Test Market Outlook: Indication
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn), By Indication, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
      • 4.4.3.1. Stage 1 Breast Cancer
      • 4.4.3.2. Stage 2 Breast Cancer
      • 4.4.3.3. Estrogen-Receptor-Positive Cancer
      • 4.4.3.4. Lymph-Node-Negative Cancer
    • 4.4.4. Market Attractiveness Analysis: Indication
  • 4.5. Global Breast Recurrence Score Test Market Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Hospitals
      • 4.5.3.2. Specialty Cancer Centers
      • 4.5.3.3. Diagnostic Centers
      • 4.5.3.4. Cancer Research Institutions
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Breast Recurrence Score Test Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Breast Recurrence Score Test Market Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Indication
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. Test Kits
    • 6.4.2. Reagents & Consumables
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 6.5.1. Stage 1 Breast Cancer
    • 6.5.2. Stage 2 Breast Cancer
    • 6.5.3. Estrogen-Receptor-Positive Cancer
    • 6.5.4. Lymph-Node-Negative Cancer
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Hospitals
    • 6.6.2. Specialty Cancer Centers
    • 6.6.3. Diagnostic Centers
    • 6.6.4. Cancer Research Institutions
  • 6.7. Market Attractiveness Analysis

7. Europe Breast Recurrence Score Test Market Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Indication
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. Test Kits
    • 7.4.2. Reagents & Consumables
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 7.5.1. Stage 1 Breast Cancer
    • 7.5.2. Stage 2 Breast Cancer
    • 7.5.3. Estrogen-Receptor-Positive Cancer
    • 7.5.4. Lymph-Node-Negative Cancer
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Hospitals
    • 7.6.2. Specialty Cancer Centers
    • 7.6.3. Diagnostic Centers
    • 7.6.4. Cancer Research Institutions
  • 7.7. Market Attractiveness Analysis

8. East Asia Breast Recurrence Score Test Market Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Indication
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. Test Kits
    • 8.4.2. Reagents & Consumables
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 8.5.1. Stage 1 Breast Cancer
    • 8.5.2. Stage 2 Breast Cancer
    • 8.5.3. Estrogen-Receptor-Positive Cancer
    • 8.5.4. Lymph-Node-Negative Cancer
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Hospitals
    • 8.6.2. Specialty Cancer Centers
    • 8.6.3. Diagnostic Centers
    • 8.6.4. Cancer Research Institutions
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Breast Recurrence Score Test Market Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Indication
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. Test Kits
    • 9.4.2. Reagents & Consumables
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 9.5.1. Stage 1 Breast Cancer
    • 9.5.2. Stage 2 Breast Cancer
    • 9.5.3. Estrogen-Receptor-Positive Cancer
    • 9.5.4. Lymph-Node-Negative Cancer
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Hospitals
    • 9.6.2. Specialty Cancer Centers
    • 9.6.3. Diagnostic Centers
    • 9.6.4. Cancer Research Institutions
  • 9.7. Market Attractiveness Analysis

10. Latin America Breast Recurrence Score Test Market Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Indication
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. Test Kits
    • 10.4.2. Reagents & Consumables
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 10.5.1. Stage 1 Breast Cancer
    • 10.5.2. Stage 2 Breast Cancer
    • 10.5.3. Estrogen-Receptor-Positive Cancer
    • 10.5.4. Lymph-Node-Negative Cancer
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Hospitals
    • 10.6.2. Specialty Cancer Centers
    • 10.6.3. Diagnostic Centers
    • 10.6.4. Cancer Research Institutions
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Breast Recurrence Score Test Market Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Indication
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. Test Kits
    • 11.4.2. Reagents & Consumables
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 11.5.1. Stage 1 Breast Cancer
    • 11.5.2. Stage 2 Breast Cancer
    • 11.5.3. Estrogen-Receptor-Positive Cancer
    • 11.5.4. Lymph-Node-Negative Cancer
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Hospitals
    • 11.6.2. Specialty Cancer Centers
    • 11.6.3. Diagnostic Centers
    • 11.6.4. Cancer Research Institutions
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. ThermoFisher Scientific
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Exact Sciences (Genome Health Inc.)
    • 12.3.3. NanoString Technologies, Inc.
    • 12.3.4. Foundation Medicine, Inc
    • 12.3.5. Illumina, Inc
    • 12.3.6. Hologic Inc (Biotheranostic)
    • 12.3.7. Biocartis
    • 12.3.8. Roche Diagnostics
    • 12.3.9. Epic Sciences
    • 12.3.10. Qiagen
    • 12.3.11. Abbott
    • 12.3.12. Myriad Genetics, Inc
    • 12.3.13. Guardant Health
    • 12.3.14. Agendia
    • 12.3.15. Genomic Health
    • 12.3.16. iCAD
    • 12.3.17. CancerIQ
    • 12.3.18. Siemens Healthineers
    • 12.3.19. General Electric Company
    • 12.3.20. Koninklijke Philips NV

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations